Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384797 · ClinicalTrials.gov registry record
Blood Biomarker in Early Parkinson's Disease
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 65
- Enrollment target
NCT03384797 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 65 participants.
The verdict
NCT03384797 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2019-01-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03384797
The ClinicalTrials.gov registry entry for NCT03384797 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03384797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03384797 about?
NCT03384797 is a clinical study titled "Blood Biomarker in Early Parkinson's Disease". Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to meas...
What is the current status of trial NCT03384797?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2018-01-22. Estimated completion is 2019-01-07.
Who is sponsoring clinical trial NCT03384797?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.